Compare · EW vs NTRB
EW vs NTRB
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Nutriband Inc. (NTRB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and NTRB operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $60.62B, about 892.2x NTRB ($68.0M).
- EW has been more active in the news (12 items in the past 4 weeks vs 1 for NTRB).
- EW has more recent analyst coverage (25 ratings vs 1 for NTRB).
- Company
- Edwards Lifesciences Corporation
- Nutriband Inc.
- Price
- -
- -
- Market cap
- $60.62B
- $68.0M
- 1M return
- +20.69%
- -
- 1Y return
- +25.38%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 1
- Recent ratings
- 25
- 1
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Nutriband Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 101 shares, decreasing direct ownership by 0.69% to 14,606 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $64,531 worth of shares (619 units at $104.25) as part of a pre-agreed trading plan (SEC Form 4)
- CEO Zovighian Bernard J exercised 23,100 shares at a strike of $72.68 and sold $2,379,779 worth of shares (23,100 units at $103.02) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr exercised 48,900 shares at a strike of $72.68 and sold $5,039,311 worth of shares (48,900 units at $103.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.00% to 22,798 units (SEC Form 4)
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Edwards Lifesciences upgraded by Robert W. Baird with a new price target
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Third Quarter Results
- Edwards Lifesciences upgraded by Truist with a new price target
Latest NTRB
- Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System
- Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
- Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
- Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
- SEC Form 25-NSE filed by Nutriband Inc.
- Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
- Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
- Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
- Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch